342 related articles for article (PubMed ID: 31649670)
21. Imaging α-GalCer-Activated iNKT Cells in a Hepatic Metastatic Environment.
Babes L; Shim R; Kubes P
Cancer Immunol Res; 2022 Jan; 10(1):12-25. PubMed ID: 34785505
[TBL] [Abstract][Full Text] [Related]
22. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
[TBL] [Abstract][Full Text] [Related]
23. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.
Croudace JE; Curbishley SM; Mura M; Willcox CR; Illarionov PA; Besra GS; Adams DH; Lammas DA
BMC Immunol; 2008 Dec; 9():71. PubMed ID: 19055753
[TBL] [Abstract][Full Text] [Related]
24. The development of airway hyperreactivity in T-bet-deficient mice requires CD1d-restricted NKT cells.
Kim HY; Pichavant M; Matangkasombut P; Koh YI; Savage PB; DeKruyff RH; Umetsu DT
J Immunol; 2009 Mar; 182(5):3252-61. PubMed ID: 19234223
[TBL] [Abstract][Full Text] [Related]
25. Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
Schneiders FL; Huijts CM; Mantici A; Menks MA; Scotet E; Veerhuis R; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2015 May; 158(1):92-9. PubMed ID: 25796193
[TBL] [Abstract][Full Text] [Related]
26. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.
Guillaume J; Pauwels N; Aspeslagh S; Zajonc DM; Elewaut D; Van Calenbergh S
Bioorg Med Chem; 2015 Jul; 23(13):3175-82. PubMed ID: 26003341
[TBL] [Abstract][Full Text] [Related]
28. Self-glycerophospholipids activate murine phospholipid-reactive T cells and inhibit iNKT cell activation by competing with ligands for CD1d loading.
Halder RC; Tran C; Prasad P; Wang J; Nallapothula D; Ishikawa T; Wang M; Zajonc DM; Singh RR
Eur J Immunol; 2019 Feb; 49(2):242-254. PubMed ID: 30508304
[TBL] [Abstract][Full Text] [Related]
29. Redirecting iNKT Cell Antitumor Immunity with α-GalCer/CD1d-scFv Fusion Proteins.
Zhang L; Donda A
Methods Mol Biol; 2021; 2388():175-180. PubMed ID: 34524672
[TBL] [Abstract][Full Text] [Related]
30. CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.
Schneiders FL; Prodöhl J; Ruben JM; O'Toole T; Scheper RJ; Bonneville M; Scotet E; Verheul HM; de Gruijl TD; van der Vliet HJ
Cancer Immunol Res; 2014 Aug; 2(8):732-40. PubMed ID: 24934445
[TBL] [Abstract][Full Text] [Related]
31. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.
Pellicci DG; Patel O; Kjer-Nielsen L; Pang SS; Sullivan LC; Kyparissoudis K; Brooks AG; Reid HH; Gras S; Lucet IS; Koh R; Smyth MJ; Mallevaey T; Matsuda JL; Gapin L; McCluskey J; Godfrey DI; Rossjohn J
Immunity; 2009 Jul; 31(1):47-59. PubMed ID: 19592275
[TBL] [Abstract][Full Text] [Related]
32. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
[TBL] [Abstract][Full Text] [Related]
33. The GM2 ganglioside inhibits iNKT cell responses in a CD1d-dependent manner.
Pereira CS; Ribeiro H; Pérez-Cabezas B; Cardoso MT; Alegrete N; Gaspar A; Leão-Teles E; Macedo MF
Mol Genet Metab; 2018 Sep; 125(1-2):161-167. PubMed ID: 30030044
[TBL] [Abstract][Full Text] [Related]
34. In contrast to other species, α-Galactosylceramide (α-GalCer) is not an immunostimulatory NKT cell agonist in horses.
Dossa RG; Alperin DC; Garzon D; Mealey RH; Brown WC; Jervis PJ; Besra GS; Cox LR; Hines SA
Dev Comp Immunol; 2015 Mar; 49(1):49-58. PubMed ID: 25445911
[TBL] [Abstract][Full Text] [Related]
35. Structure and binding kinetics of three different human CD1d-alpha-galactosylceramide-specific T cell receptors.
Gadola SD; Koch M; Marles-Wright J; Lissin NM; Shepherd D; Matulis G; Harlos K; Villiger PM; Stuart DI; Jakobsen BK; Cerundolo V; Jones EY
J Exp Med; 2006 Mar; 203(3):699-710. PubMed ID: 16520393
[TBL] [Abstract][Full Text] [Related]
36. Novel in vitro invariant natural killer T cell functional assays.
Balasko A; Graydon C; Fowke KR
J Immunol Methods; 2021 Dec; 499():113171. PubMed ID: 34706265
[TBL] [Abstract][Full Text] [Related]
37. Atypical natural killer T-cell receptor recognition of CD1d-lipid antigens.
Le Nours J; Praveena T; Pellicci DG; Gherardin NA; Ross FJ; Lim RT; Besra GS; Keshipeddy S; Richardson SK; Howell AR; Gras S; Godfrey DI; Rossjohn J; Uldrich AP
Nat Commun; 2016 Feb; 7():10570. PubMed ID: 26875526
[TBL] [Abstract][Full Text] [Related]
38. Structural determination of lipid antigens captured at the CD1d-T-cell receptor interface.
Brennan PJ; Cheng TY; Pellicci DG; Watts GFM; Veerapen N; Young DC; Rossjohn J; Besra GS; Godfrey DI; Brenner MB; Moody DB
Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8348-8353. PubMed ID: 28716901
[TBL] [Abstract][Full Text] [Related]
39. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
[TBL] [Abstract][Full Text] [Related]
40. 4"-O-Alkylated α-Galactosylceramide Analogues as iNKT-Cell Antigens: Synthetic, Biological, and Structural Studies.
Janssens J; Bitra A; Wang J; Decruy T; Venken K; van der Eycken J; Elewaut D; Zajonc DM; van Calenbergh S
ChemMedChem; 2019 Jan; 14(1):147-168. PubMed ID: 30556652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]